metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
versus docetaxel
	atezolizumab alone
	OAK (all population), 2016 Lancet 2017;389:255-265 Clin Lung Cancer 2018; 19:e405-e415 Clin Lung Cancer 2018; 19:441-449.e4 Eur. J. Cancer 2019; 107:124-132 J Thorac Oncol 2018; 13:1156-1170 J Med Econ 2019; 22:625-637 Lung Cancer 2019 Feb;128:105-112. NCT02008227	RCT	mNSCLC - L2 - all population	atelozumab	docetaxel	patients with locally advanced or metastatic (IIIB and IV) non-small cell lung cancer (NSCLC) who have failed platinum therapy	613 / 612	some concern	conclusif	demonstrated 20 % decrease in deaths (OS) (PE)
	POPLAR, 2016 Lancet 2016;387:1837-46 J Immunother Cancer 2019; 7:249 NCT01903993	RCT	mNSCLC - L2 - all population	atezolizumab	docetaxel	patients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy	144 / 143	some concern	conclusif	demonstrated 27 % decrease in deaths (OS) (PE)